Nicholas Piramal to spin off

Desai, Suresh Thakur
May 1998
Chemical Business;May/Jun98, Vol. 12 Issue 5/6, p95
Trade Publication
Reports on the approval by shareholders of Nicholas Piramal of the spin-off of the glass and bulk drug units.


Related Articles

  • Nicholas Piramal net rises by 23%. Desai, Suresh Thakur // Chemical Business;May/Jun98, Vol. 12 Issue 5/6, p95 

    Reports on the financial performance of Nicholas Piramal India Ltd. in the fiscal period 1997-98.

  • Fine Chemical Firms Plan Multimillion-Dollar Investments. Scott, Alex // Chemical Week;2/28/2007, Vol. 169 Issue 7, p29 

    The article reports on the Informex fine and specialty chemicals expo held in San Francisco, California in February 2007. The event was awash with companies planning to install fine chemical manufacturing capacity. According to Cambrex it will spend $30 million-$60 million within the next three...

  • Innovations. O'Driscoll, Catherine // ICIS Chemical Business;6/26/2006, Vol. 1 Issue 25, p43 

    The article presents news briefs on the global chemical industry. Researchers at the University of Florence in Italy have discovered a new form of solid carbon dioxide that promises to be useful for making ultra-hard glass or coatings for microelectronic devices. Nicholas Piramal has announced...

  • The beginning of the end for EU specialities? Baker, John // European Chemical News;10/31/2005, Vol. 83 Issue 2169, p5 

    This article reports on the effort of Asian producers to acquire assets in Europe as of October 2005. It was said that such efforts were made to gain market access and technology. According to reports, Avecia revealed it has struck a deal to sell its pharmaceutical custom synthesis business in...

  • NPH snags Avecia Pharmaceuticals.  // Chemical Market Reporter;10/31/2005, Vol. 268 Issue 15, p7 

    Reports on the acquisition of Great Britain-based custom synthesis and manufacturing firm Avecia Pharmaceuticals by Mumbai, India-based Nicholas Piramal India Ltd. Amount involved in the acquisition deal; Plan of Avecia to put the proceeds towards a deficit in the company's pension fund;...

  • Laporte and Piramal form JV in India.  // Chemical Market Reporter;08/17/98, Vol. 254 Issue 7, p3 

    Reports on Laporte PLC's joint venture with Nicholas Piramal India Ltd., named Laporte Piramal, to manufacture fine chemicals including pharmaceutical intermediates and food additives. Management of the combined company by Laporte Fine Chemicals; Facilities being constructed under the joint...

  • Danisco Cultor Licenses Maltol In India to Stay Competitive. Landau, Peter // Chemical Market Reporter;09/20/99, Vol. 256 Issue 12, p16 

    Reports that Danisco Cultor has sold its Veltol and Veltol-Plus brands of maltol and ethyl maltol and will license related technology to Nicholas Piramal India Ltd. Company's goal for selling its maltol brands and technology to Nicholas Piramal; Agreement signed by Danisco Cultor with the joint...

  • Window on financial developments. Desai, Suresh Thakur // Chemical Business;Feb2002, Vol. 16 Issue 2, p41 

    Presents updates on the chemical industry in India as of February 2002. Profits of Nerolac Paints for the quarter ended December 31, 2001; Net profit of Asian Paints for the quarter ended December 31, 2001; Loan of Nicholas Piramal group.

  • DIGEST.  // Chemical Week;3/31/2004, Vol. 166 Issue 11, p43 

    Presents news briefs on the pharmaceutical and fine chemicals industries as of March 31, 2004. Contract awarded to Bachem to manufacture the peptide drug candidate Lcatibant for Jerini, a private startup pharma company; Collaboration of pharma and fine chemicals firm Nicholas Piramal with Vera...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics